title: Predicting glioblastoma response to bevacizumab through marker profiling?
authors.affiliation: Neurology Clinic, University Hospital Heidelberg and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Kessler
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab